Beryl Drugs Limited is an established Indian pharmaceutical manufacturer specializing in the production of **Bulk Drugs**, **Polypropylene (PP) Bottles**, and **Form-Fill-Seal (FFS) Infusions**. Operating as a single-segment entity under **Ind AS 108**, the company provides critical medical supplies to a diverse client base encompassing government institutions, corporate hospitals, and private distributors. --- ### **Core Manufacturing Capabilities & Technical Upgradation** The company’s operational backbone is its specialized manufacturing facility, which recently underwent a significant technical transformation to align with global standards. * **WHO-GMP & Schedule M Compliance:** To meet the **revised Schedule M** and **WHO-GMP norms**, the company temporarily halted its **FFS (Form-Fill-Seal) Section** in **January 2025**. This strategic downtime culminated in the successful attainment of **WHO-GMP certification** on **March 27, 2025**, positioning the company for higher-tier domestic and international contracts. * **Capacity Optimization:** Management has established a clear roadmap to increase plant capacity utilization from the current **65% to 90%**. * **Operational Oversight:** Day-to-day factory functions—including procurement, labor engagement, and machinery maintenance—are supervised by a dedicated **Whole Time Director (WTD)** to ensure lean manufacturing processes. --- ### **Strategic Market Expansion & Distribution Channels** Beryl Drugs employs a multi-channel sales strategy to mitigate market concentration risk and maximize reach. * **Domestic Footprint:** The company operates **3 marketing offices** in India, serving a network of over **30 corporate customers** and **3 primary channel partners**. * **The Aminova Partnership:** A pivotal 2-year agreement (**January 2026 – January 2028**) has been signed with **M/s. Aminova Infusions Pvt. Ltd.** This partnership focuses on: * Distribution across the high-demand states of **Maharashtra** and **Gujarat**. * Facilitating penetration into **government institutions**. * Acting as a springboard for **overseas exports**. * **Pricing Strategy:** Products are sold at **ex-factory rates** based on prevailing market prices, allowing the company to remain competitive against both organized and unorganized players. --- ### **Financial Performance & Capital Structure** Beryl Drugs is currently in a phase of **capital conservation**, prioritizing debt reduction and internal reinvestment over immediate dividend payouts. **Comparative Financial Highlights** | Metric (₹ in Lakhs) | March 31, 2025 | March 31, 2024 | March 31, 2023 | | :--- | :--- | :--- | :--- | | **Net Profit** | **57.88** | **76.86** | *N/A* | | **Net Debt** | **407.35** | **509.39** | **454.21** | | **Total Equity** | **950.25** | **892.33** | **806.63** | | **Net Debt to Equity Ratio** | **0.43** | **0.57** | **0.56** | * **Deleveraging:** The company successfully reduced its **Net Debt to Equity ratio** to **0.43**, reflecting a disciplined approach to financial liabilities. * **Equity Profile:** The **Paid-up Equity Share Capital** stands at **₹5.71 Crores**. Notably, **74.89%** of the share capital is **dematerialized**. * **Asset Monetization:** The company owns land and a godown in **Indore** with a fair value exceeding **₹3.39 Crores**, generating a steady **Rental Income** of **₹12.73 Lakhs** per annum. * **Dividend Policy:** The Board has opted to **not recommend dividends** for the recent fiscal year, redirecting all internal accruals toward **project implementation** and **asset growth**. --- ### **Sustainability & Cost Optimization Initiatives** To combat profit volatility and rising energy costs, the company is integrating renewable energy and streamlining its cost structure. * **Solar Integration:** Beryl is installing a **200KVA Solar Plant** at its factory premises. This project is funded via a **₹45.00 Lacs** term loan from **Punjab National Bank**, aimed at reducing long-term utility expenses. * **Operational Efficiency:** Management is actively implementing measures to **reduce incurred costs** and scale income to reverse the recent dip in net profit (from **₹76.86 Lacs** to **₹57.88 Lacs**). --- ### **Risk Management & Regulatory Landscape** The company operates under a formal **Risk Management Policy** to navigate a complex regulatory and competitive environment. * **Regulatory Hurdles:** Operations faced a setback when the **State FDA** suspended a portion of the facility on **February 11, 2025**. Following rectification and compliance reports, the suspension was lifted on **November 28, 2025**. * **Credit Risk:** The company manages defaults via an **Expected Credit Loss** method. In FY2025, the company wrote off **₹23.75 Lakhs** in trade receivables due to non-recoverability. * **Market Competition:** Significant pressure exists from the **unorganized sector** and new entrants in the **PP Bottle** and **FFS** segments. * **Macroeconomic Factors:** The business remains sensitive to **inflation**, **taxation policy changes**, and **global economic shifts**. **Movement in Allowance for Expected Credit Losses** | Description | FY 2024-25 (₹ in Lakhs) | FY 2023-24 (₹ in Lakhs) | | :--- | :---: | :---: | | Opening Balance | **58.58** | **39.25** | | Impairment loss recognized | **24.25** | **27.95** | | Amounts written off | **(23.74)** | **(8.62)** | | **Closing Balance** | **59.09** | **58.58** | --- ### **Leadership & Governance Framework** The company has reinforced its board to ensure continuity and strategic oversight for its expansion programs. * **Executive Re-appointments:** **Mr. Sanjay Sethi** has been re-appointed as **Managing Director** for a **5-year term** (effective **December 11, 2025**). * **Board Expansion:** * **Mr. Shailendra Pathak** appointed as **Whole Time Director** (effective Feb 2026). * **Mrs. Neha Sarda** appointed as **Independent Director**. * **Ms. Shreya Saraf** re-appointed as **Independent Director** through **May 2029**. * **Compliance Status:** There are no reported frauds under **Section 143(12)** and no pending proceedings under the **Insolvency and Bankruptcy Code, 2016**. All previous audit concerns regarding the creation of charges on bank loans (specifically a **₹1.75 crore** loan from Kotak Mahindra Bank) have been resolved, with the balance reaching **Nil** as of March 2025.